The independent data monitoring committee of the phase III SANET-p study of surufatinib in advanced neuroendocrine tumors has recommended that the study end early as the pre-defined primary endpoint of progression free survival had already been met.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
